Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 5/20 | 0.59 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.59 |
| ▸ | RORC | P51449 | 2/20 | 0.50 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.45 |
| ▸ | SETD7 | Q8WTS6 | 2/20 | 0.43 |
| ▸ | FPR2 | P25090 | 4/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.42 |
| ▸ | FPR3 | P25089 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1673567 | 1.00 | NR1H2 (0.59) | NR1H2NR1H3RORCABHD6ROCK2 | |
| SCHEMBL83834 | 1.00 | NR1H2 (0.59) | NR1H2NR1H3RORCABHD6ROCK2 | |
| SCHEMBL82172 | 0.93 | NR1H2 (0.57) | NR1H2NR1H3RORCABHD6ROCK2 | |
| SCHEMBL12988184 | 0.93 | NR1H2 (0.57) | NR1H2NR1H3RORCABHD6ROCK2 | |
| SCHEMBL22772313 | 0.88 | NR1H2 (0.47) | NR1H2NR1H3RORCABHD6ROCK2 | |
| SCHEMBL521801 | 0.87 | NR1H2 (0.49) | NR1H2NR1H3RORCABHD6ROCK2 | |
| SCHEMBL83391 | 0.87 | MEN1 (0.53) | NR1H2NR1H3ABHD6ROCK2 | |
| SCHEMBL1673737 | 0.87 | MEN1 (0.53) | NR1H2NR1H3ABHD6ROCK2 | |
| SCHEMBL1673736 | 0.87 | MEN1 (0.53) | NR1H2NR1H3ABHD6ROCK2 | |
| SCHEMBL4712983 | 0.87 | NR1H2 (0.58) | NR1H2NR1H3RORCABHD6ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129377-B2 | 6-(pyridinyl)-4-pyrimidone derivates as tau protein kinase 1 inhibitors | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-03-06 | — | — | US | disclosed |
| EP-1805164-B9 | 6-(PYRIDINYL)-4-PYRIMIDONE DERIVATES AS TAU PROTEIN KINASE 1 INHIBITORS | MITSUBISHI TANABE PHARMA CORP (JP) | 2011-09-07 | — | — | EP | disclosed |
| EP-2308854-A1 | 2,3,6-trisubstituted-4-pyrimidone derivatives | Sanofi-Aventis (FR) | 2011-04-13 | — | — | EP | disclosed |
| EP-2305651-A1 | 2,3,6-trisubstituted-4-pyrimidone derivatives | Mitsubishi Tanabe Pharma Corporation (JP) | 2011-04-06 | — | — | EP | disclosed |
| EP-1805164-B1 | 6-(PYRIDINYL)-4-PYRIMIDONE DERIVATES AS TAU PROTEIN KINASE 1 INHIBITORS | MITSUBISHI TANABE PHARMA CORP (JP) | 2011-02-23 | — | — | EP | disclosed |
| EP-2266969-A2 | 6-(Pyridinyl)-4-pyrimidone derivatives as tau protein kinase 1 inhibitors | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-12-29 | — | — | EP | disclosed |
| EP-2261224-A2 | 6-(Pyridinyl)-4-pyrimidone derivatives as tau protein kinase 1 inhibitors | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-12-15 | — | — | EP | disclosed |
| US-20090239864-A1 | 6- (PYRIDINYL) -4-PYRIMIDONE DERIVATES AS TAU PROTEIN KINASE 1 INHIBITORS | MITSUBISHI PHARMA CORPORATION (JP) | 2009-09-24 | — | — | US | disclosed |
| US-7504411-B2 | 2,3,6-Trisubstituted-4-pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-03-17 | — | — | US | disclosed |
| EP-1805164-A2 | 6-(PYRIDINYL)-4-PYRIMIDONE DERIVATES AS TAU PROTEIN KINASE 1 INHIBITORS | Mitsubishi Pharma Corporation (JP) | 2007-07-11 | — | — | EP | disclosed |
| US-20060252768-A1 | 2,3,6-Trisubstituted-4-pyrimidone derivatives | SANOFI (FR) | 2006-11-09 | — | — | US | disclosed |
| WO-2006036015-A2 | 6- (PYRIDINYL) -4-PYRIMIDONE DERIVATES AS TAU PROTEIN KINASE 1 INHIBITORS | MITSUBISHI PHARMA CORPORATION (JP) | 2006-04-06 | — | — | WO | disclosed |
| EP-1608630-A1 | 2, 3, 6-TRISUBSTITUTED-4-PYRIMIDONE DERIVATIVES | Mitsubishi Pharma Corporation (JP) | 2005-12-28 | — | — | EP | disclosed |
| WO-2004085408-A1 | 2, 3, 6-TRISUBSTITUTED-4-PYRIMIDONE DERIVATIVES | MITSUBISHI PHARMA CORPORATION (JP) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239864-A1 | 6- (PYRIDINYL) -4-PYRIMIDONE DERIVATES AS TAU PROTEIN KINASE 1 INHIBITORS | MAPT, TTBK1, PSEN1 | NR1H2 2500/4885NR1H3 2928/4885RORC 1650/4885 |
| US-20060252768-A1 | 2,3,6-Trisubstituted-4-pyrimidone derivatives | PSEN1, PSEN2, MAPT | NR1H2 3604/4885NR1H3 3999/4885RORC 1594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.